Dyne Therapeutics Q2 2026: Loss Widens as Pipeline Advances; Cash Runway Extended to Q2 2028

summarizeSummary

Dyne Therapeutics reported a wider Q2 2026 net loss of $178.6M as R&D spending surged to advance its neuromuscular pipeline. Cash and equivalents of $898.5M, plus $405M from a July offering, fund operations into Q2 2028, beyond the January 2027 PDUFA date for its lead DMD candidate.

check_boxKey Events · Earnings and Guidance · DYN

• Q2 2026 Net Loss Widens to $178.6M

  Net loss increased 61% year-over-year to $178.6M, driven by a 53% rise in R&D expenses to $152.2M as the company advanced its lead programs z-rostudirsen and z-basivarsen through late-stage clinical trials and manufacturing scale-up.

• Cash Runway Extended to Q2 2028

  Cash, equivalents, and marketable securities totaled $898.5M as of June 30, 2026. Combined with $405M in net proceeds from a July 2026 follow-on offering, the company expects its cash runway to extend into the second quarter of 2028, past the anticipated PDUFA date for z-rostudirsen.

• FDA Accepts BLA for z-rostudirsen with Priority Review

  The FDA accepted the Biologics License Application for z-rostudirsen in Duchenne muscular dystrophy amenable to exon 51 skipping and granted Priority Review with a PDUFA target action date of January 21, 2027. A potential U.S. launch is expected in Q1 2027 if approved.

• Phase 3 Trials Underway for Lead Programs

  The confirmatory Phase 3 FORZETTO trial for z-rostudirsen was initiated in May 2026, and dosing began in the Phase 3 HARMONIA trial for z-basivarsen in July 2026. Both trials are designed to support conversion to traditional approval and ex-U.S. marketing applications.

auto_awesomeAnalysis · DYN · Life Sciences

Dyne's Q2 2026 loss deepened to $178.6M from $110.9M a year ago, driven by a 53% jump in R&D spending as the company pushes its lead programs toward potential approvals. The cash position remains strong at $898.5M, and with $405M in net proceeds from a July follow-on offering, runway extends into Q2 2028 — past the expected PDUFA date for z-rostudirsen in January 2027. The FDA accepted the BLA with Priority Review, and the confirmatory Phase 3 trials for both z-rostudirsen and z-basivarsen are underway. The company also cleared IND for its FSHD candidate, DYNE-302. The spending ramp is expected but manageable given the capital raised; the key risk is execution on regulatory milestones and eventual commercial launch.